Pilar de la Huerta
Chief Executive Officer
Pilar de la Huerta has accumulated an extensive experience in the pharma and biotech sector over the last 20 years.
She joined Genetrix group as a CEO in 2010, moving to SYGNIS after the merger done between Xpol, Genetrix subsidiary, and SYGNIS AG in october 2012. From 2006 to 2010, she was a strategic consultant within several companies, such as Viamed Salud Group, where she was responsible for R&D and New Business and was appointed CEO of the two most innovative companies within the Group: Araclon Biotech, SL. and Viamed Technology Investments. Before that, she was CEO at Neuropharma (Noscira, Zeltia Group) and assumed various responsibilities within the Zeltia Group, (the biggest quoted biotech holding in Spain).
Pilar holds a Master Degree in Business and Administration by the UCM and has completed the IESE’s Advanced Management Program (AMP) and Program for Management Development (PMD) courses in the Navarra University.
She has been appointed as board member of several Spanish companies during the last 10 years, but have left most of them to dedicate her time 100% to the new SYGNIS. Currently, she is part of the management board of SYGNIS.
Dr. José Ramón Fernández
Dr. José Ramón Fernández holds an MBA and a Doctorate from the University of Oviedo.
In his long trajectory within the pharmaceutical industry, Dr. Fernández has worked in diverse management positions in R&D, Production, and Plant Management, in facilities focused on active ingredients (oral and sterile), final pharmaceutical presentation (tablets, effervescent capsules, granulates end suspensions) as well as sterile pharmaceutical presentations (parenteral solution, single doses and ampoules).
He has successfully undergone multiple FDA inspections for both active ingredients (oral and sterile) and final pharmaceutical presentation, owns 2 patents, and has authored 33 articles in science journals. Dr. Fernández is currently a member of several professional associations and Vice-President of the Association of Chemists of Asturias and León.
Rafael Guerras Bernabé
Chief Financial Officer
Rafael Guerras Bernabé has an Economics Degree from the University of Saint Louis, Missouri, USA, and an MBA from San Pablo University-CEU in Madrid, Spain.
He brings to ADL BioPharma over 15 years of experience as chief financial officer in companies in very diverse sectors such as the construction sector, the hotel industry, naval management, banking and the chemical and pharmaceutical sector, having been an active member of the boards of directors in these companies.
Rafael has lead multi-disciplinary teams focused on the efficiency and optimization of the financial and human resources departments, and has reached the highest standards of quality in his career trajectory. Moreover, he has participated in legislation compliance teams to establish protocols and procedures to improve quality in the organizations where he has furthered his career.
Dr. Manuel López Nieto
Dr. Manuel J. Lopez Nieto has a Biology Doctorate from the University of Salamanca, Spain, and has completed an Executive Development Programme at the University of Navarra Business School-IESE.
His work experience includes several pharmaceutical and biopharmaceutical companies such as Genentech, Lonza and 3P Bio. Dr. Lopez contributes to ADL Biopharma his extensive experience in biotechnological processes and the production of proteins and other molecules through fermentation, at both laboratory and industrial scale.
In addition, he has published 22 articles in international magazines as well as 27 lectures for national and international congresses, and has registered 8 patents. He has also been involved in several national and international research projects in collaboration with various universities and companies.
Dra. Mª José García
Quality Unit Director
Dr. María José García graduated in Pharmacy with a major in Medical and Industrial Pharmacy, and completed an Executive Development Programme from European University of Madrid.
She holds a Doctorate in Pharmacy from the University Complutense of Madrid.
She has developed her professional career in different pharmaceutical and biopharmaceutical companies such as Italfarmaco, Leti, Sanofi, Pasteur and Bayer.
Dr. García has accumulated an extensive experience as a Pharmaceutical Regulatory Affairs Director [mainly in sterile and bio-based products] and as a Quality Director [responsible for implementing GMP and GxP guidelines].
Currently, she belongs to several professional associations and groups working on the design and review of domestic and international regulations concerning the pharmaceutical industry [medicines for human and veterinary use].
Dr. Jorge Villamaña
Head of Project Development
Dr. Jorge Villamaña García owns a Ph.D. degree in Chemistry by the University of Oviedo (Spain) and a Program of Managerial Development by IESE Business School [University of Navarra; Spain).
He has developed all his professional activity in ADL BioPharma.. Dr. Villamaña García contributes to ADL Biopharma with a deep expertise in Biotechnology and Chemical Production Processes, chemical production of oral and sterile pharmaceutical products and extensive training in all activities related to industrial activity.
Alicia del Corral
Marketing Director and Head of Sales
Alicia del Corral is a Pharmacy graduate from the University of Seville and has a Pharmaceutical Industry Master’s Degree from CESIF.
Her career has evolved within the pharmaceutical industry at companies like CHEMO and GSK, always in an international B2B environment.
She has worked in different positions in business areas such as Supply Chain, Sales, and Marketing, and, among other responsibilities, has been in charge of managing and developing international client accounts, creating marketing materials, organizing promotional events, and managing corporate brand and image.